J&J, U of Toronto in neuroscience deal

The Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) partnered with the University of Toronto's Center for Collaborative Drug Research (CCDR) to develop therapies to treat mood disorders and Alzheimer's disease (AD). J&J's Innovation Center in California arranged the deal.

The collaboration will be known as Neuroscience Catalyst. A joint steering committee comprising Janssen and university representatives will screen early stage research proposals. Janssen and the university will co-fund about 10 selected projects over a three-year period. Janssen declined to disclose the amount each project will receive. The first call for proposals will occur in November. ...